Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWhy This Matters for Your Career
Novartis is hiring 10 roles related to this product
CAPTOPRIL (captopril) by Novartis is clinical pharmacology mechanism of action the mechanism of action of captopril has not yet been fully elucidated. Approved for hypertension, diabetic nephropathy (proteinuria > 500 mg/day) in patients with type i insulin-dependent diabetes mellitus, retinopathy and 8 more indications. First approved in 1996.
CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent…
Worked on CAPTOPRIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions
Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moNovartis is hiring 10 roles related to this product